Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 2
2002 1
2006 1
2007 1
2008 2
2009 2
2010 2
2011 1
2015 5
2016 2
2017 6
2018 3
2019 2
2020 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis.
Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, Sage J, Campbell JE, Ribich S, Rekhtman N, Dowlati A, Massion PP, Rudin CM, Poirier JT. Gardner EE, et al. Among authors: ribich s. Cancer Cell. 2017 Feb 13;31(2):286-299. doi: 10.1016/j.ccell.2017.01.006. Cancer Cell. 2017. PMID: 28196596 Free PMC article.
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Fedoriw A, Rajapurkar SR, O'Brien S, Gerhart SV, Mitchell LH, Adams ND, Rioux N, Lingaraj T, Ribich SA, Pappalardi MB, Shah N, Laraio J, Liu Y, Butticello M, Carpenter CL, Creasy C, Korenchuk S, McCabe MT, McHugh CF, Nagarajan R, Wagner C, Zappacosta F, Annan R, Concha NO, Thomas RA, Hart TK, Smith JJ, Copeland RA, Moyer MP, Campbell J, Stickland K, Mills J, Jacques-O'Hagan S, Allain C, Johnston D, Raimondi A, Porter Scott M, Waters N, Swinger K, Boriack-Sjodin A, Riera T, Shapiro G, Chesworth R, Prinjha RK, Kruger RG, Barbash O, Mohammad HP. Fedoriw A, et al. Among authors: ribich sa. Cancer Cell. 2019 Jul 8;36(1):100-114.e25. doi: 10.1016/j.ccell.2019.05.014. Epub 2019 Jun 27. Cancer Cell. 2019. PMID: 31257072 Free article.
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V. Italiano A, et al. Among authors: ribich s. Lancet Oncol. 2018 May;19(5):649-659. doi: 10.1016/S1470-2045(18)30145-1. Epub 2018 Apr 9. Lancet Oncol. 2018. PMID: 29650362 Clinical Trial.
RNA-modifying proteins as anticancer drug targets.
Boriack-Sjodin PA, Ribich S, Copeland RA. Boriack-Sjodin PA, et al. Among authors: ribich s. Nat Rev Drug Discov. 2018 Jun;17(6):435-453. doi: 10.1038/nrd.2018.71. Epub 2018 May 18. Nat Rev Drug Discov. 2018. PMID: 29773918 Review.
An inside job.
Bianco AC, Ribich S, Kim BW. Bianco AC, et al. Among authors: ribich s. Endocrinology. 2007 Jul;148(7):3077-9. doi: 10.1210/en.2007-0371. Endocrinology. 2007. PMID: 17575061 No abstract available.
A Mass Spectrometric Assay of METTL3/METTL14 Methyltransferase Activity.
Buker SM, Gurard-Levin ZA, Wheeler BD, Scholle MD, Case AW, Hirsch JL, Ribich S, Copeland RA, Boriack-Sjodin PA. Buker SM, et al. Among authors: ribich s. SLAS Discov. 2020 Apr;25(4):361-371. doi: 10.1177/2472555219878408. Epub 2019 Oct 4. SLAS Discov. 2020. PMID: 31585521 Free article.
30 results